A comprehensive view of Weight Issues. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Consumer Wellness Market Intelligence Service.
Eli Lilly lists Phase 2 interventional clinical trial to investigate weight management with LY3841136 compared with placebo in adult participants with obesity or overweight
Published:
January 31, 2024
by Contify Life Science News
|
Executive Perspective: Nestle working on products to accompany weight-loss drugs like Ozempic, Wegovy and Mounjaro, as the food industry evolves in response to the soaring popularity of the appetite-killing drugs, says CEO Mark Schneider
Published:
October 19, 2023
by Forbes
|
Commentary: Action on Sugar’s recent call for a ban on child-orientated packaging on cereal is a call for creeping regulatory overreach to accelerate, ignores the science around weight loss, represents a slippery slope toward complete brand erosion
Published:
September 11, 2023
by Grocer (UK)
|
Goldman Sachs sees obesity dragging world GDP down by US$4T in 2035, but weight-loss drugs could change that; Novo Nordisk study finds Wegovy reduced chance of heart attacks, strokes and cardiovascular deaths by 20%, could help with sleep apnea, addiction
Published:
September 08, 2023
by Business Insider
|
Commentary: Despite popularity of weight loss drugs, US retailers see minimal profit due to low gross margins on branded medications; while increased foot traffic could lead to multiple purchases for Walmart, impact varies for Rite Aid, CVS and Walgreens
Published:
August 22, 2023
by MarketLine
|
Ask us about our Consumer Wellness market view